Home
THTX
THTX News

Latest Theratechnologies Inc. (THTX) News on March 29, 2025

MT Newswires

3 days ago

Theratechnologies Shares Soar Premarket on FDA Approval of New Formulation of Excess Abdominal Fat Treatment

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

GlobeNewswire

4 days ago

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

MT Newswires

17 days ago

Theratechnologies Presents Ibalizumab Data in Virologic Suppression

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

GlobeNewswire

17 days ago

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

GlobeNewswire

17 days ago

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ...

GuruFocus.com

a month ago

Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ...

MT Newswires

a month ago

Theratechnologies Q4 Net Loss Widens, but Revenue Rises

Associated Press Finance

a month ago

Theratechnologies: Fiscal Q4 Earnings Snapshot

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

GlobeNewswire

a month ago

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Theratechnologies Inc (TSX:TH) Q4 2024: Everything You Need to Know Ahead of Earnings

GuruFocus.com

a month ago

Theratechnologies Inc (TSX:TH) Q4 2024: Everything You Need to Know Ahead of Earnings

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

GlobeNewswire

a month ago

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

MT Newswires

a month ago

Theratechnologies Resumes Distribution of EGRIFTA SV

Theratechnologies Provides Update on EGRIFTA SV® Supply

GlobeNewswire

3 months ago

Theratechnologies Provides Update on EGRIFTA SV® Supply

MT Newswires

3 months ago

Theratechnologies Submits FDA Prior Approval Supplement for Egrifta Manufacturing Changes

MT Newswires

3 months ago

Theratechnologies 10% Higher as Submits Prior Approval Supplement to FDA For Egrifta SV Distribution

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

GlobeNewswire

3 months ago

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

MT Newswires

4 months ago

Theratechnologies Receives March 2025 PDUFA Goal Date For Updated Tesamorelin F8 Formulation sBLA

MT Newswires

4 months ago

Theratechnologies Gets Medical Review Committee Approval for Higher Doses of TH1902 at Phase 1b Trial

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

GlobeNewswire

4 months ago

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

Theratechnologies enters exclusive licensing agreement with Ionis

TipRanks

4 months ago

Theratechnologies enters exclusive licensing agreement with Ionis

MT Newswires

4 months ago

Theratechnologies to Commercialize Two RNA-targeted Medicines in Canada

MT Newswires

4 months ago

Theratechnologies Acquires Canadian Rights to 2 RNA Medicines From Ionis Pharmaceuticals

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

GlobeNewswire

4 months ago

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

MT Newswires

4 months ago

Theratechnologies Resumes Production of EGRIFTA SV

Theratechnologies Announces Resumed Production of EGRIFTA SV®

GlobeNewswire

4 months ago

Theratechnologies Announces Resumed Production of EGRIFTA SV®

Theratechnologies secures up to $75M in new credit facilities

TipRanks

4 months ago

Theratechnologies secures up to $75M in new credit facilities

Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec

GlobeNewswire

4 months ago

Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec

MT Newswires

4 months ago

Theratechnologies Submits Updated Tesamorelin F8 Formulation Application for FDA Review

Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

GlobeNewswire

4 months ago

Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability

Simply Wall St.

4 months ago

Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability

Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

GlobeNewswire

5 months ago

Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

MT Newswires

5 months ago

Theratechnologies Unveils Study Design of PROMISE-US Trial of Ibalizumab

Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

GlobeNewswire

5 months ago

Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

Theratechnologies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

6 months ago

Theratechnologies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Theratechnologies Inc (THTX) Q3 2024 Earnings Call Highlights: Strong Profitability Amid ...

GuruFocus.com

6 months ago

Theratechnologies Inc (THTX) Q3 2024 Earnings Call Highlights: Strong Profitability Amid ...

MT Newswires

6 months ago

Theratechnologies Up 12% in U.S. Premarket Trading After Reporting Q3 Swing to Profit

Associated Press Finance

6 months ago

Theratechnologies: Fiscal Q3 Earnings Snapshot

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

GlobeNewswire

6 months ago

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

Earnings to Watch: Theratechnologies Inc (TSX:TH) Reports Q3 2024 Result

GuruFocus.com

6 months ago

Earnings to Watch: Theratechnologies Inc (TSX:TH) Reports Q3 2024 Result

MT Newswires

6 months ago

Theratechnologies to Present Data Next Week Highlighting Advances in Treatment in People with HIV

Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV

GlobeNewswire

6 months ago

Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV

Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update

GlobeNewswire

6 months ago

Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update

Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays

Benzinga

6 months ago

Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays

MT Newswires

6 months ago

Theratechnologies Warns of Egrifta SV Supply Shortage After Shutdown at Contract Manufacturer's Facility

MT Newswires

6 months ago

Theratechnologies Sees Risk of Supply Disruption for Its EGRIFTA SV Drug in Early 2025

Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025

GlobeNewswire

6 months ago

Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025

Theratechnologies to Present at Upcoming Investor Conferences in September

GlobeNewswire

7 months ago

Theratechnologies to Present at Upcoming Investor Conferences in September

Positive Signs As Multiple Insiders Buy Theratechnologies Stock

Simply Wall St.

7 months ago

Positive Signs As Multiple Insiders Buy Theratechnologies Stock

Why Fast-paced Mover Theratechnologies (THTX) Is a Great Choice for Value Investors

Zacks

8 months ago

Why Fast-paced Mover Theratechnologies (THTX) Is a Great Choice for Value Investors

Theratechnologies Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

8 months ago

Theratechnologies Second Quarter 2024 Earnings: Beats Expectations

Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock

Zacks

8 months ago

Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock

HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars

Benzinga

9 months ago

HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars

Associated Press Finance

9 months ago

Theratechnologies: Fiscal Q2 Earnings Snapshot

MT Newswires

9 months ago

Theratechnologies Swings to Q2 Profit as Revenue Rises 25%; Confirms FY24 Guidance

Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024

GlobeNewswire

9 months ago

Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update

GlobeNewswire

9 months ago

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update

Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability

Simply Wall St.

10 months ago

Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

Yahoo Finance Video

10 months ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

GlobeNewswire

10 months ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

Reuters

10 months ago

California seeks company profits in Big Oil climate lawsuit

USA TODAY

10 months ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

GlobeNewswire

10 months ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Business Wire

10 months ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

GlobeNewswire

10 months ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

10 months ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum

Zacks

10 months ago

Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum

MT Newswires

10 months ago

Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate

GlobeNewswire

10 months ago

Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

Theratechnologies Reports on its Annual Meeting of Shareholders

GlobeNewswire

a year ago

Theratechnologies Reports on its Annual Meeting of Shareholders

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting

GlobeNewswire

a year ago

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting

Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

a year ago

Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

GlobeNewswire

a year ago

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire

a year ago

Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Associated Press Finance

a year ago

Theratechnologies: Fiscal Q1 Earnings Snapshot

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

GlobeNewswire

a year ago

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

GlobeNewswire

a year ago

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Theratechnologies Appoints Elina Tea to its Board of Directors

GlobeNewswire

a year ago

Theratechnologies Appoints Elina Tea to its Board of Directors

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

GlobeNewswire

a year ago

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform

GlobeNewswire

a year ago

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform

Theratechnologies Announces Update on its Preclinical Oncology Research Program

GlobeNewswire

a year ago

Theratechnologies Announces Update on its Preclinical Oncology Research Program

Theratechnologies Appoints Jordan Zwick to its Board of Directors

GlobeNewswire

a year ago

Theratechnologies Appoints Jordan Zwick to its Board of Directors

Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

GlobeNewswire

a year ago

Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

GlobeNewswire

a year ago

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA

GlobeNewswire

a year ago

Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA

Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock

Zacks

a year ago

Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock

Theratechnologies Full Year 2023 Earnings: Misses Expectations

Simply Wall St.

a year ago

Theratechnologies Full Year 2023 Earnings: Misses Expectations

Associated Press Finance

a year ago

Theratechnologies: Fiscal Q4 Earnings Snapshot

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

GlobeNewswire

a year ago

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

GlobeNewswire

a year ago

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

GlobeNewswire

a year ago

Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

GlobeNewswire

a year ago

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

Positive Signs As Multiple Insiders Buy Theratechnologies Stock

Simply Wall St.

a year ago

Positive Signs As Multiple Insiders Buy Theratechnologies Stock

Business Wire

a year ago

ClearBridge MLP Funds Announce Proposed Mergers and Updates for Tender Offers

Associated Press Finance

a year ago

Northrim: Q4 Earnings Snapshot

Northrim BanCorp Earns $6.6 million, or $1.19 Per Diluted Share, in Fourth Quarter 2023, and $25.4 Million, or $4.49 Per Diluted Share, for the Year Ended December 31, 2023

GlobeNewswire

a year ago

Northrim BanCorp Earns $6.6 million, or $1.19 Per Diluted Share, in Fourth Quarter 2023, and $25.4 Million, or $4.49 Per Diluted Share, for the Year Ended December 31, 2023

What Makes AirSculpt Technologies, Inc. (AIRS) a New Strong Buy Stock

Zacks

a year ago

What Makes AirSculpt Technologies, Inc. (AIRS) a New Strong Buy Stock

Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

GlobeNewswire

a year ago

Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application

GlobeNewswire

a year ago

Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application

Gap (NYSE:GPS) Q3 Earnings: Leading The Apparel Retailer Pack

StockStory

a year ago

Gap (NYSE:GPS) Q3 Earnings: Leading The Apparel Retailer Pack

Business Wire

a year ago

First Trust High Income Long/Short Fund Declares its Monthly Common Share Distribution of $0.105 Per Share for February

Share on Social Networks: